DCTH (Delcath Systems Inc)
Insider Trading Activity
Every open-market purchase and sale reported by DCTH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | ELIZABETH CZEREPAK | Director | A | — | — |
| 2026-05-14 | Gil Aharon | Director | A | — | — |
| 2026-05-14 | STEVEN A J SALAMON | Director | A | — | — |
| 2026-05-14 | John Richard Sylvester | Director | A | — | — |
| 2026-05-14 | Bridget A Martell | Director | A | — | — |
| 2026-03-06 | Sandra Pennell | Chief Financial Officer | Buy | — | — |
| 2026-03-03 | GERARD J MICHEL | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2026-02-18 | Vojo Vukovic | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-02-18 | David L. Hoffman | GEN'L COUNSEL, CCO & SECY | A | — | — |
| 2026-02-18 | GERARD J MICHEL | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-02-18 | Sandra Pennell | Chief Financial Officer | A | — | — |
| 2026-02-18 | Martha S. Rook | CHIEF OPERATING OFFICER | A | — | — |
| 2026-02-18 | Kevin Muir | GM INTERVENTIONAL ONCOLOGY | A | — | — |
| 2025-11-25 | John Richard Sylvester | Director | Buy | — | — |
| 2025-11-13 | GERARD J MICHEL | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2025-06-13 | Vojo Vukovic | CHIEF MEDICAL OFFICER | M | — | — |
| 2025-05-19 | John Richard Sylvester | Director | A | — | — |
| 2025-05-19 | Gil Aharon | Director | A | — | — |
| 2025-05-19 | STEVEN A J SALAMON | Director | A | — | — |
| 2025-05-19 | ELIZABETH CZEREPAK | Director | A | — | — |
| 2025-05-19 | Bridget A Martell | Director | A | — | — |
| 2025-05-09 | Gil Aharon | Director | X | — | — |
| 2025-05-09 | Gil Aharon | Director | X | — | — |
| 2025-05-09 | STEVEN A J SALAMON | Director | X | — | — |
| 2025-02-07 | Sandra Pennell | Chief Financial Officer | A | — | — |
| 2025-02-07 | Martha S. Rook | CHIEF OPERATING OFFICER | A | — | — |
| 2025-02-07 | Kevin Muir | GM INTERVENTIONAL ONCOLOGY | A | — | — |
| 2025-02-07 | Vojo Vukovic | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-02-07 | GERARD J MICHEL | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-02-07 | David L. Hoffman | GEN'L COUNSEL, CCO & SECY | A | — | — |
| 2024-12-27 | STEVEN A J SALAMON | Director | C | — | — |
| 2024-12-26 | Rosalind Advisors, Inc. | Director | C | — | — |
| 2024-12-26 | Gil Aharon | Director | C | — | — |
| 2024-11-01 | Gil Aharon | Director | MIXED | — | — |
| 2024-11-01 | STEVEN A J SALAMON | Director | MIXED | — | — |
| 2024-11-01 | Gil Aharon | Director | MIXED | — | — |
| 2024-10-23 | GERARD J MICHEL | CHIEF EXECUTIVE OFFICER | M | — | — |
| 2024-05-28 | STEVEN A J SALAMON | Director | A | — | — |
| 2024-05-28 | Bridget A Martell | Director | A | — | — |
| 2024-05-28 | Gil Aharon | Director | A | — | — |
| 2024-05-28 | ELIZABETH CZEREPAK | Director | A | — | — |
| 2024-05-28 | ROGER G PHD STOLL | Director | MIXED | — | — |
| 2024-05-28 | John Richard Sylvester | Director | A | — | — |
| 2024-05-16 | Gil Aharon | Director | MIXED | — | — |
| 2024-05-16 | STEVEN A J SALAMON | Director | MIXED | — | — |
| 2024-05-16 | Gil Aharon | Director | MIXED | — | — |
| 2024-05-16 | STEVEN A J SALAMON | Director | MIXED | — | — |
| 2024-05-16 | Rosalind Advisors, Inc. | Director | MIXED | — | — |
| 2024-05-16 | Rosalind Advisors, Inc. | Director | MIXED | — | — |
| 2024-03-20 | Martha S. Rook | CHIEF OPERATING OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,534,493 | — |
| — | Director | 4,483,178 | — |
| — | Director | 3,013,468 | — |
| — | CHIEF EXECUTIVE OFFICER | 342,034 | — |
| — | CHIEF MEDICAL OFFICER | 168,882 | — |
| — | Chief Financial Officer | 77,018 | — |
| — | GEN'L COUNSEL, CCO & SECY | 74,330 | — |
| — | CHIEF OPERATING OFFICER | 41,526 | — |
| — | President and CEO | 25,021 | — |
| — | GM INTERVENTIONAL ONCOLOGY | 18,582 | — |
| — | Director | 14,936 | — |
| — | Director | 9,309 | — |
| — | See Remarks | 6,051 | — |
| — | Director | 6,014 | — |
| — | Director | 6,001 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DCTH quote page; the site-wide leaderboard is on the insider transactions hub.